Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 301–400 of 1,003
Krashia, P., Nobili, A., & D'Amelio, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00123 · Cited by 71
Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease
Cai, H., Ao, Z., Hu, L., Moon, Y., Wu, Z., Lu, H.-C., Kim, J., & Guo, F. (2020) · The Analyst · doi:10.1039/d0an01373k · Cited by 76
Involvement of molecular chaperone in protein-misfolding brain diseases
Wankhede, N. L., Kale, M. B., Upaganlawar, A. B., Taksande, B. G., Umekar, M. J., Behl, T., Abdellatif, A. A. H., Bhaskaran, P. M., Dachani, S. R., Sehgal, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112647 · Cited by 77
The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
Tousi, B. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61309 · Cited by 65
ApoE2 and Alzheimer′s disease: time to take a closer look
Zhao, L., & Wu, L. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.179044 · Cited by 69
“Since its discovery in 1906, extensive research has been undertaken to define AD pathogenesis and to develop treatments; however, the cause of AD remains largely unknown and no therapeutic success has been achieved in over 200 AD drug trials conducted in the past decade (Cummings et al., 2014).”
BackgroundVisual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 80
“However, there are no diseases modifying therapies currently available (Cummings et al. 2014).”
BackgroundAssociation of peripheral blood DNA methylation level with Alzheimer’s disease progression
Li, Q. S., Vasanthakumar, A., Davis, J. W., Idler, K. B., Nho, K. T., Waring, J. F., Saykin, A. J., & Initiative, A. D. N. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01179-2 · Cited by 74
“difficulty in identifying patients at early stages of the disease [1].”
BackgroundDrosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives
Bouleau, S., & Tricoire, H. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142802 · Cited by 69
“However, until now, all these trials failed to delay the disease [6].”
Prati, F., De Simone, A., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Bertozzi, S. M., Perez, D. I., Andrisano, V., Perez-Castillo, A., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00121 · Cited by 68
Liu, Y., Deng, Y., Liu, H., Yin, C., Li, X., & Gong, Q. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.11.002 · Cited by 68
“However, these drugs provide limited treatment efficacy and have strong adverse effects, eventually restricting to clinical application (Cummings et al., 2015).”
BackgroundKetogenic Diet for the Treatment and Prevention of Dementia: A Review
Davis, J. J., Fournakis, N. A., & Ellison, J. M. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720901785 · Cited by 77
“However, only 1 new drug (memantine) has been granted an FDA indication from all of these trials since 2002.(14) In the absence of a highly effective symptomatic or diseasemodifying pharmacologic agent, lifestyle modification is the cornerstone of effective prevention and alleviation of cognitive decline.”
BackgroundTDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer’s Disease Mouse Models
Zhao, J. J., Shi, Q., Tian, H., Li, Y., Liu, Y., Xu, Z., Robert, A., Liu, Q., & Meunier, B. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00621 · Cited by 70
Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases
Pandian, S. R. K., Vijayakumar, K. K., Murugesan, S., & Kunjiappan, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09575 · Cited by 86
Puentes-Díaz, N., Chaparro, D., Morales-Morales, D., Flores-Gaspar, A., & Alí-Torres, J. (2023) · ACS Omega · doi:10.1021/acsomega.2c06939 · Cited by 67
Romero-Durán, F., Alonso, N., Yáñez, M., Caamaño, O., García-Mera, X., & González‐Díaz, H. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.019 · Cited by 71
“The situation with other neurodegenerative processes like amyotrophic lateral sclerosis or the diverse parkinsonisms is not better (Cummings et al., 2014).”
BackgroundBachurin, S. O., Shevtsova, E. F., Makhaeva, G. F., Grigoriev, V. V., Boltneva, N. P., Kovaleva, N. V., Lushchekina, S. V., Shevtsov, P. N., Neganova, M. E., Redkozubova, O. M., et al. (2017) · Scientific Reports · doi:10.1038/srep45627 · Cited by 66
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Carvalho, C., Gaspar, A., Knight, A., & Vicente, L. (2018) · Animals · doi:10.3390/ani9010012 · Cited by 82
“4% (in Alzheimer’s trials [91]) to 20% [92].”
Leonard, H. L., Blauwendraat, C., Krohn, L., Faghri, F., Iwaki, H., Ferguson, G. D., Day-Williams, A., Stone, D. J., Singleton, A., Nalls, M. A., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106283 · Cited by 68
Hackett, K., Mis, R. E., Drabick, D. A. G., & Giovannetti, T. (2020) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617719001449 · Cited by 70
Huang, H.-J., Chen, J.-L., Liao, J.-F., Chen, Y., Chieu, M.-W., Ke, Y.-Y., Hsu, C.-C., Tsai, Y.-C., & Hsieh‐Li, H. M. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03426-8 · Cited by 68
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
Oukoloff, K., Coquelle, N., Bartolini, M., Naldi, M., Le Guevel, R., Bach, S., Josselin, B., Ruchaud, S., Catto, M., Pisani, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.063 · Cited by 65
“Despite efforts over the last few decades of b th academic research teams and pharmaceutical companies, no curative treatment has emerged yet.[10-12] An attrition factor in the development of curative drugs is the fact that the aetiology of AD is not fully understood.”
BackgroundLuo, Y., Sun, Y., Tian, X., Zheng, X., Wang, X., Li, W., Wu, X., Shu, B., & Hou, W. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.619543 · Cited by 64
“AD patients and animal models have obvious cholinergic dysfunction involving abnormal ACh production and degradation, including choline acetyltransferase (ChAT) and acetylcholinesterase (AChE), respectively (Davies and Maloney, 1976; Perry et al., 1977; Schliebs and Arendt, 2011).”
BackgroundReassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Goldwaser, E. L., Acharya, N. K., Sarkar, A., Godsey, G., & Nagele, R. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160284 · Cited by 65
“The 99.6% failure rate for AD drugs in clinical trials has been both unfortunate and disheartening [1].”
InfluentialSleep and hippocampal neurogenesis: Implications for Alzheimer’s disease
Kent, B. A., & Mistlberger, R. E. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.004 · Cited by 70
Manyevitch, R., Protas, M., Scarpiello, S., Deliso, M., Bass, B., Nanajian, A., Chang, M., Thompson, S. M., Khoury, N., Gonnella, R., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205014666170921122458 · Cited by 65
“6% drug failure rate between 2002 and 2012 [1]).”
Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer’s disease
Muñoz-Moreno, E., Tudela, R., López-Gil, X., & Soria, G. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0346-2 · Cited by 65
“Later, anti-Aβ agents were successfully tested in preclinical models but failed in clinical studies owing to the poor translation between preclinical and clinical research [9, 10].”
BackgroundAn arabinogalactan from fruits of Lycium barbarum L. inhibits production and aggregation of Aβ42
Zhou, L., Liao, W., Xia, C., Yue, H., Li, S., & Ding, K. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.05.022 · Cited by 69
Requirements for Animal Experiments: Problems and Challenges
Fontana, F., Figueiredo, P., Martins, J. P., & Santos, H. A. (2020) · Small · doi:10.1002/smll.202004182 · Cited by 68
Molecular estimation of neurodegeneration pseudotime in older brains
Mukherjee, S., Heath, L., Preuss, C., Jayadev, S., Garden, G. A., Greenwood, A. K., Sieberts, S. K., De Jager, P. L., Ertekin-Taner, N., Carter, G. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19622-y · Cited by 63
Ishii, M., & Iadecola, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.029 · Cited by 64
Dal‐Pan, A., Dudonné, S., Bourassa, P., Bourdoulous, M., Tremblay, C., Desjardins, Y., & Calon, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160281 · Cited by 70
Ece, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1583606 · Cited by 64
Firth, N. C., Primativo, S., Brotherhood, E., Young, A. L., Yong, K. X. X., Crutch, S. J., Alexander, D. C., & Oxtoby, N. P. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12083 · Cited by 76
Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Self-citationModulating 5-Ht 4 and 5-Ht 6 Receptors in Alzheimer’S Disease Treatment
Lalut, J., Karila, D., Dallemagne, P., & Rochais, C. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0031 · Cited by 67
Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise
McGurran, H., Glenn, J. M., Madero, E. N., & Bott, N. T. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180958 · Cited by 63
“Moreover, there are currently no viable disease-modifying agents for AD, and clinical trials on novel pharmaceutical treatments have experienced an extremely high failure rate [4].”
Alghazwi, M., Smid, S. D., Karpiniec, S. S., & Zhang, W. Y. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.10.168 · Cited by 66
Shukla, R., Munjal, N. S., & Singh, T. R. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.06.008 · Cited by 69
Are rodent models of Parkinson’s disease behaving as they should?
Vingill, S., Connor‐Robson, N., & Wade‐Martins, R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.10.021 · Cited by 69
Dietary Regulation of Gut-Brain Axis in Alzheimer’s Disease: Importance of Microbiota Metabolites
Frausto, D. M., Forsyth, C. B., Keshavarzian, A., & Voigt, R. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.736814 · Cited by 61
CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review
Barman, N. C., Khan, M. N. M., Islam, M., Nain, Z., Roy, R. K., Haque, A., & BARMAN, S. K. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00218-z · Cited by 69
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?
Femminella, G. D., Livingston, N. R., Raza, S., van der Doef, T., Frangou, E., Love, S., Busza, G., Calsolaro, V., Carver, S., Holmes, C., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00784-w · Cited by 61
Kabir, M. T., Uddin, M. S., Jeandet, P., Emran, T. B., Mitra, S., Albadrani, G. M., Sayed, A. A., Abdel‐Daim, M. M., & Simal‐Gándara, J. (2021) · Marine Drugs · doi:10.3390/md19050251 · Cited by 71
“Although the number of AD individuals is growing, there are only five approved drugs currently in use for AD treatment in the United States [35].”
BackgroundMolinuevo, J. L., Camí, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 69
“In this scenario, trials in mild moderate AD have been consistently negative during the last decade [15], and although we are still waiting for the results of ongoing prodromal AD trials, intervention studies on asymptomatic individuals appear as highly relevant and promising, before substantial irreversible neuronal…”
BackgroundBennett, D. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002256 · Cited by 61
The Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease
Desler, C., Lillenes, M. S., Tønjum, T., & Rasmussen, L. J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170616110111 · Cited by 61
“flected in the fact that successful interventions for treating or preventing AD remain elusive and the fact that clinical trials for interventions based on existing hypotheses about the role of Aβ and senile plaques in AD report limited or no success [5].”
BackgroundFiorito, J., Vendôme, J., Saeed, F., Staniszewski, A., Zhang, H., Yan, S., Deng, S., Arancio, O., & Landry, D. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00979 · Cited by 60
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 72
Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease
Onyango, I. G. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224362 · Cited by 64
“far, all clinical trials designed to lower levels of Aβ by either blocking activity of β or γ secretases, preventing Aβ aggregation, or promoting Aβ clearance by immunotherapy have failed (Cummings et al., 2014; Feldman et al., 2014) emphasizing an urgent need to find new therapies for AD.”
BackgroundN-alkylpiperidine carbamates as potential anti-Alzheimer’s agents
Košak, U., Strašek, N., Knez, D., Jukič, M., Žakelj, S., Zahirović, A., Pišlar, A. H., Brazzolotto, X., Nachon, F., Kos, J., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112282 · Cited by 66
Microglia: Friend and foe in tauopathy
Odfalk, K. F., Bieniek, K. F., & Hopp, S. C. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102306 · Cited by 60
Nutrition as Metabolic Treatment for Anxiety
Norwitz, N. G., & Naidoo, U. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.598119 · Cited by 73
Regulation and roles of RNA modifications in aging‐related diseases
Jiapaer, Z., Su, D., Hua, L., Lehmann, H. I., Gokulnath, P., Vulugundam, G., Song, S., Zhang, L., Gong, Y., & Li, G. (2022) · Aging Cell · doi:10.1111/acel.13657 · Cited by 65
“It is one of the most damaging aging- related neurodegenerative diseases, the prevalence of which increases as the global population ages (Cummings et al., 2014).”
BackgroundAlamro, H., Thafar, M. A., Albaradei, S., Gojobori, T., Essack, M., & Gao, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-30904-5 · Cited by 72
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
Tasaki, S., Gaiteri, C., Mostafavi, S., De Jager, P. L., & Bennett, D. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00699 · Cited by 59
“, 2015), or external factors, such as economics of trial failures in Alzheimer’s dementia (Doody et al., 2013, 2014; Cummings et al., 2014; Salloway et al., 2014).”
BackgroundComputational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer’s Disease
Petrella, J. R., Hao, W., Rao, A., Doraiswamy, P. M., & Initiative, F. T. A. D. C. M. (2019) · Computational and Mathematical Methods in Medicine · doi:10.1155/2019/6216530 · Cited by 70
Wechsler, M. E., Vela Ramirez, J. E., & Peppas, N. A. (2019) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.9b02196 · Cited by 60
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 78
Hascup, E. R., Broderick, S. O., Russell, M. K., Fang, Y., Bartke, A., Boger, H. A., & Hascup, K. N. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14634 · Cited by 63
Locus coeruleus in the pathogenesis of Alzheimer's disease: A systematic review
Chen, Y., Chen, T., & Hou, R. H. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12257 · Cited by 83
Scuteri, D., Morrone, L. A., Rombolà, L., Avato, P., Bilia, A. R., Corasaniti, M. T., Sakurada, S., Sakurada, T., & Bagetta, G. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/9416305 · Cited by 73
“New strategies targeting Aβ have been tested in order to delay AD progression, but small molecules and immunotherapy both have failed [9].”
BackgroundProtein aggregation in cell biology: An aggregomics perspective of health and disease
Cox, D., Raeburn, C., Sui, X., & Hatters, D. M. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.003 · Cited by 65
White Matter and Cognition in Traumatic Brain Injury
Filley, C. M., & Kelly, J. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180287 · Cited by 69
“Yet this pathogenetic formulation has never been indis-putably established [100], and all efforts to treat the disease by targeting its signature proteins have thus far failed [101].”
Nickel, F., Barth, J., & Kolominsky-Rabas, P. L. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0751-1 · Cited by 58
“In the light of the comparably low success rate in the development of AD drugs [39] and the limited number of agents in the current pipeline [40], the development of effective non-pharmacological interventions is of particular importance in the treatment and care of PwDs and the support of informal caregivers.”
BackgroundBrini, S., Sohrabi, H. R., Hébert, J. J., Forrest, M. R. L., Laine, M., Hämäläinen, H., Karrasch, M., Peiffer, J. J., Martins, R. N., & Fairchild, T. J. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09426-8 · Cited by 71
Scheiner, M., Hoffmann, M., He, F., Poeta, E., Chatonnet, A., Monti, B., Maurice, T., & Decker, M. W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00534 · Cited by 61
Kizhakke P., A., Olakkaran, S., Antony, A., Tilagul K., S., & Hunasanahally P., G. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.10.002 · Cited by 58
De Simone, A., La Pietra, V., Betari, N., Petragnani, N., Conte, M., Daniele, S., Pietrobono, D., Martini, C., Petralla, S., Casadei, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00507 · Cited by 56
Rudroff, T. (2024) · Neurology International · doi:10.3390/neurolint16040060 · Cited by 64
“Dozens of Alzheimer’s treatments have succeeded in animal models but failed in humans, with a success rate of only 0.4% [21].”
BackgroundInfluentialShin, S. J., Jeon, S. G., Kim, J.-I., Jeong, Y.-O., Kim, S., Park, Y. H., Lee, S.-K., Park, H. H., Hong, S. B., Oh, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123030 · Cited by 58
Veening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Boon, W. P. C., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172524 · Cited by 55
“With a failure rate of more than 99%, drug development in Alzheimer's disease has been largely unsuccessful: since 2002 over than 400 clinical trials failed due to lack of efficacy (Cummings et al., 2014; Rinaldi, 2018).”
BackgroundTaylor, M. K., Swerdlow, R. H., & Sullivan, D. K. (2019) · Nutrients · doi:10.3390/nu11081910 · Cited by 65
Effectiveness of cognitive stimulation for dementia: A systematic review and meta-analysis.
Cafferata, R. M. T., Hicks, B., & von Bastian, C. C. (2021) · Psychological Bulletin · doi:10.1037/bul0000325 · Cited by 72
“Yet, drug development efforts have been characterized by a high failure rate (99.6% for clinical trials for drugs targeting Alzheimer’s disease, Cummings et al., 2014), and existing pharmacological treatments aimed to alleviate cognitive, behavioral, and psychological symptoms of dementia have…”
BackgroundInfluentialPosner, H. B., Curiel, R. E., Edgar, C. J., Hendrix, S. B., Liu, E., Loewenstein, D., Morrison, G., Shinobu, L. A., Wesnes, K. A., & Harvey, P. D. (2017) · PubMed · Cited by 66
Antidiabetic Drugs in Alzheimer’s Disease: Mechanisms of Action and Future Perspectives
Femminella, G. D., Bencivenga, L., Petraglia, L., Visaggi, L., Gioia, L., Grieco, F. V., de Lucia, C., Komici, K., Corbi, G., Edison, P., et al. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7420796 · Cited by 56
“Of over 400 trials performed in AD from 2002 to 2012, only one has led to the approval of a medication (memantine in 2003) for its clinical use in AD, proving that drug development in AD is indeed very difficult [78].”
BackgroundBott, N. T., Hall, A., Madero, E. N., Glenn, J. M., Fuseya, N., Gills, J. L., & Gray, M. (2019) · Nutrients · doi:10.3390/nu11092258 · Cited by 56
“To date, trials targeting individuals with detectable cognitive or cognitive and functional impairment have failed [65].”
BackgroundDrug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014; Yiannopoulou et al., 2019).”
BackgroundCeppa, F., Izzo, L., Sardelli, L., Raimondi, I., Tunesi, M., Albani, D., & Giordano, C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00297 · Cited by 60
“This is apparent when considering that about 99% of clinical trials for new drugs against AD failed in the past 15 years (Cummings et al., 2014).”
BackgroundLimbocker, R., Staats, R., Chia, S., Ruggeri, F. S., Mannini, B., Xu, C. K., Perni, M., Cascella, R., Bigi, A., Sasser, L. R., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.680026 · Cited by 57
Kaur, S., Aran, K. R., Gupta, Y. K., & Singh, S. (2021) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-021-01866-8 · Cited by 63
Szałaj, N., Bajda, M., Rakoczy, J., Brus, B., Gobec, S., & Malawska, B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.045 · Cited by 55
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
Cummings, J., Aisen, P., Barton, R., Bork, J., Doody, R., Dwyer, J., Egan, J. C., Feldman, H., Lappin, D., Truyen, L., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.93 · Cited by 55
“The compromised state of AD clinical trials contributes to the low success rate of AD drug development both directly by making it difficult to demonstrate a drug-placebo difference and indirectly by discouraging investment in AD drug development by pharmaceutical and biotechnology companies (2, 7).”
BackgroundSelf-citationSalazar, S. V., Gallardo, C., Kaufman, A. C., Herber, C. S., Haas, L. T., Robinson, S., Manson, J. C., Lee, M. K., & Strittmatter, S. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0722-17.2017 · Cited by 55
Ainani, H., Bouchmaa, N., Ben Mrid, R., & El Fatimy, R. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106011 · Cited by 54
Kulas, J. A., Weigel, T. K., & Ferris, H. A. (2020) · Drug Development Research · doi:10.1002/ddr.21643 · Cited by 54
Bang, S., Lee, S., Choi, N., & Kim, H. N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002119 · Cited by 60
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C., Cho, H.-J., & Ryu, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 53
Chew, J. L., Chong, M. S., Tay, L. B. G., & Fong, Y.-L. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s93914 · Cited by 60
From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer’s Disease?: Miniperspective
Bolognesi, M. L., Gandini, A., Prati, F., & Uliassi, E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00151 · Cited by 52
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease
Rohn, T. T., Kim, N., Isho, N. F., & Mack, J. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000439 · Cited by 64
How Big Data and High-Performance Computing Drive Brain Science
Chen, S., He, Z., Han, X., He, X., Li, R., Zhu, H., Zhao, D., Dai, C., Zhang, Y., Lu, Z., et al. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.09.003 · Cited by 59
Buchanan, H., Mackay, M., Palmer, K., Tothová, K., Katsur, M., Platt, B., & Koss, D. J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01950-1 · Cited by 54
Jurcau, A. (2021) · Nutrients · doi:10.3390/nu13020282 · Cited by 54
“This may be due to the longer duration of trials, greater expenses, less well defined target biology, limited available biomarkers, as well as to the high risk of failure [13].”
BackgroundQuantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease
Ezzati, A., Initiative, A. D. N., & Lipton, R. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190822 · Cited by 60
“One strategy to overcome this problem, and simultaneously boosting the power of trials, is to only enroll individuals likely to progress based on data-driven predictive models.”
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease
Martins, M., Silva, R. V. D. S., Pinto, M. M. M., & Sousa, E. (2020) · Pharmaceuticals · doi:10.3390/ph13090242 · Cited by 59
Zielinski, M., Reyes, F. S. P., Gremer, L., Schemmert, S., Frieg, B., Schäfer, L. U., Willuweit, A., Donner, L., Elvers, M., Nilsson, L. N. G., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01484-4 · Cited by 53
“Considering that most patients with Alzheimer’s disease have a sporadic background, one can speculate that this might be one important reason why the failure rate of clinical trials has been so high 28 .”
Background
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
